)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
Cessatech
Cessatech (CESSA) investor relations material
Cessatech Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary28 May, 2026
Executive summary
Advanced CT001, a nasal spray for pediatric acute pain, toward commercialization in the US and Europe, with regulatory reviews ongoing and manufacturing validation extending the US launch timeline.
Presented positive clinical data for CT001 at a major pediatric pain medicine conference, strengthening scientific engagement.
Expanded intellectual property portfolio with new patents in key markets.
Financial highlights
Net revenue for Q1 2026 was DKK 0, compared to DKK 1,243,000 in Q1 2025, reflecting no new milestone payments.
Operating loss was DKK -3,762,000, an improvement from DKK -5,610,000 in Q1 2025, due to lower development costs.
Net loss for the period was DKK -3,228,000, compared to DKK -4,296,000 in Q1 2025.
Cash at bank at period end was DKK 5,316,000.
Earnings per share was DKK -0.17, compared to DKK -0.25 in Q1 2025.
Outlook and guidance
US launch of CT001 delayed due to extended manufacturing validation and quality assurance; focus remains on completing these steps for market entry.
EMA review of CT001 ongoing, with minimal clinical and CMC costs expected for the remainder of 2026 as development concludes.
Cash position, supported by an extended DKK 10 million loan facility, is considered sufficient for the next 18–24 months.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cessatech
- CT001 advanced to regulatory review, financials improved, but going concern risk persists.CESSA
Q4 202527 Feb 2026 - CT001 advanced to EMA review, with Q3 loss and cash boosted by a successful share issue.CESSAQ3 202513 Nov 2025
- Strong clinical results and capital raise drive regulatory and commercial progress for CT001.CESSAQ2 202521 Aug 2025
- Proveca deal, clinical progress, and improved Q3 results position Cessatech for future growth.CESSAQ3 202413 Jun 2025
- Q2 2024 saw no revenue, a DKK -3.4M loss, and key progress toward CT001's US launch.CESSAQ2 202413 Jun 2025
- Net loss narrowed and cash strengthened as Cessatech advanced CT001 toward commercialization.CESSAQ4 20249 Jun 2025
- Q1 2025 saw Cessatech advance CT001 toward EMA submission, with net loss in line with expectations.CESSAQ1 20256 Jun 2025
Next Cessatech earnings date
Q2 202628 Aug, 2026
Cessatech
Next Cessatech earnings date
Q2 202628 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage